CAR-T Therapy in China for International Patients

Yes. International patients can receive NMPA-approved commercial CAR-T therapies (福可苏® / 赛恺泽®) at licensed Chinese hematology centers. Formal medical acceptance, eligibility confirmation, and treatment plans are issued directly by the treating hospital after examining complete medical records.

Under formal National Medical Products Administration (NMPA) regulatory labels, commercial BCMA CAR-T therapies in China (Equecabtagene Autoleucel / Eque-cel and Zevorcabtagene Autoleucel / Zevor-cel) are approved for patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent). However, extensive global and domestic trial data increasingly support earlier intervention at first or second relapse, demonstrating deeper remissions and prolonged progression-free survival due to superior baseline T-cell fitness.

Because China is the origin and primary manufacturing center for both Eque-cel and Zevor-cel, biopharmaceutical manufacturers and accredited hospital teams have the institutional capacity to support earlier-line treatment under hospital ethics and clinical evaluation frameworks. In particular, international patients paying out-of-pocket do not draw on China’s domestic basic medical insurance (BMI) public funds, and qualified tertiary centers generally welcome eligible international candidates following multidisciplinary team (MDT) review.

If you are exploring earlier-line CAR-T, CMDN can coordinate a free pre-travel medical records review with credentialed hematology teams to evaluate your eligibility and provide a definitive clinical conclusion before you travel.

Treat it as a signal to verify, not as a confirmed hospital quote. The net commercial drug alone starts at about ¥950,000 before any hospital care — and that is the cheaper of the two products. 福可苏® (Eque-cel) carries no international-patient reduction as of 8 September 2026, so its net drug alone is about ¥1,166,000. On the discounted product, a public general-ward episode paid directly to the hospital in RMB has an indicative drug-plus-hospital range of ¥1,030,000–¥1,170,000, usually with Mandarin-only ward care. Private international hospital care has a higher indicative range of ¥1,300,000–¥1,450,000. Hospital-side ranges are CMDN planning estimates, not published hospital packages or observed patient-bill ranges. They cover work-up, apheresis, lymphodepletion, inpatient monitoring, supportive medicines and early follow-up. Bridging therapy, ICU care and travel/living costs are additional; the upper values are not cost caps. Use the cost calculator for current currency conversions. A third-party “all-inclusive private package with lodging and translation” under $150,000 should be checked against these costs. Ask which licensed product the quote is based on — the answer moves the floor by ¥216,000 — which hospital account the money goes to, and what is included besides the drug. CMDN can review the written offer with you.

Under Chinese regulatory and human genetic resource rules, interventional clinical trials in China almost exclusively enroll Chinese domestic residents with valid national identification. Legitimate hospitals rarely enroll overseas patients into clinical trials. If someone offers to place a foreign patient in a free or low-cost Chinese trial, ask which ethics approval applies and why a non-resident would be eligible. CMDN can help you read that claim.

List prices differ by product: ¥1,166,000 for 福可苏® (Eque-cel) and ¥1,150,000 for 赛恺泽® (Zevor-cel). The ¥200,000 manufacturer reduction for international patients now applies to 赛恺泽® (Zevor-cel) only — 福可苏® (Eque-cel) withdrew it effective 8 September 2026. Net cell-product cost is therefore about ¥950,000 for zevor-cel and ¥1,166,000 for eque-cel. Neither reduction is covered by a published manufacturer announcement, and no end date has been published for the zevor-cel reduction, so ask the treating hospital to confirm the applicable reduction in writing before you budget. Hospital stay, work-up, bridging, and non-routine ICU are billed separately and vary by public ward, public international department, or private international hospital.

Public general wards offer the lowest overall costs and massive clinical volume, but ward rounds are in Mandarin and international onboarding is challenging. Public international medical centers (IMCs) share the same senior doctors, offer English liaison support for admissions, and have higher fees. Private international hospitals provide dedicated international pathways, stronger English clinical communication, and free S2 visa assistance at the highest overall cost. CMDN lists all three tiers neutrally so you can decide.

English is the exception, not the default. On public hospital general wards, ward rounds and nursing care are conducted entirely in Mandarin, and foreign patients must arrange their own professional medical interpreter. Public IMCs usually have bilingual administrative staff for registration, but bedside medical rounds may still require interpretation. Only a few private international hospitals sustain direct clinical English communication between attending oncologists and patients.

You do not necessarily need a specialized medical visa before traveling. Citizens from approximately 50 countries can enter China visa-free for initial medical evaluations, and others can travel on a standard tourist visa (L-visa). If an extended stay or formal medical visa (S2) is needed, candidate private international hospitals can provide invitation letters at no charge. You do not need to pay any commercial broker for visas or hospital access.

CMDN is an independent nonprofit patient community: we do not sell treatment packages, charge consultation fees, or handle patient medical payments. All medical treatment fees, deposits, and drug costs are billed and wired directly to the licensed treating hospital's official bank account with formal itemized medical invoices.